The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

Inclusion Criteria: * Prepubertal girls at Tanner stage I, with age ≥ 2 years and \< 12 years at the time of informed consent signature. * With clinical manifestations of Turner syndrome and a confirmed diagnosis of Turner syndrome based on peripheral blood karyotype analysis (karyotype analysis of at least 30 metaphase cells). * At screening, bone age is delayed relative to chronological age or advanced by no more than 1 year (i.e., bone age - chronological age ≤ 1 year). * At screening, height is below -2 standard deviations (-2SD) of the mean for age and gender; height reference is shown in Appendix 1. * No prior systematic pharmacological growth-promoting treatment (continuous use for ≥ 1 month), including but not limited to growth hormone, insulin-like growth factor 1 (IGF-1), etc. * Thyroid hormone replacement therapy (if applicable) received prior to randomization should be maintained on a stable regimen for at least 4 weeks. * The legal guardian understands and signs the informed consent form; participants aged ≥ 8 years shall also sign the informed consent form. For participants aged under 8 years who are capable of expressing assent, their assent shall be clearly documented. Exclusion Criteria: * Subjects with closed epiphyses. * Patients with Turner syndrome carrying Y chromosome or Y-chromosome-derived fragments and without gonadectomy. * Other types of growth and development abnormalities, including but not limited to growth hormone deficiency (GHD), Noonan sy…